Halozyme Therapeutics competitorsClear all
Blueprint Medicines's top competitors include Karyopharm Therapeutics.
 Blueprint Medicines Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers. |  Karyopharm Therapeutics Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for the treatment of cancer and other major diseases. | |
Founding Date | Founding Date 2011 | Founding Date 2008 |
Type | Type Public | Type Subsidiary |
Tags | ||
Locations | Locations Cambridge, US HQ Amsterdam, NL Lugano, CH Zug, CH Cambridge, US | Locations Newton, US HQ München, DE Giv'atayim, IL Providence, US |
Employees | Employees 38376% increase | Employees 481 |
Alexa Website Rank | Alexa Website Rank 365252 | Alexa Website Rank 230559 |
Employee Rating | Employee Rating 4.2 | Employee Rating 3.6 |
Financial | ||
Revenue (est.) | Revenue (est.) $793.7m (FY, 2020) | Revenue (est.) $108.1m (FY, 2020) |
Net income | Net income $313.9m (FY, 2020) | Net income ($196.3m) (FY, 2020) |
Funding | ||
Total funding raised | Total funding raised $ 115m | Total funding raised $ 248.7m |
For sources of this data, please see the company profile
View company profiles
Karyopharm Therapeutics
HQ
Newton, US
Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for the treatment of cancer and other major diseases.
View company